Finance

Beta
Lists
STOK:NASDAQ
Stoke Therapeutics Inc
$31.11
0.00%
(0.00) 1D
$31.00
-0.35% (-0.11)
Pre-market
Closed: Jun 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for STOK...
Mkt. cap
1.94B
Avg. vol.
636.81K
Volume
2.27K
52-wk high
$40.22
52-wk low
$11.17
EPS
-$2.83
Beta
1.17
Shares outstanding
62.28M
No. of employees
170
Mkt. cap
1.94B
Avg. vol.
636.81K
Volume
2.27K
52-wk high
$40.22
52-wk low
$11.17
EPS
-$2.83
Beta
1.17
Shares outstanding
62.28M
No. of employees
170
News stories
From sources across the web
About Stoke Therapeutics Inc
CEO-
Employees170
Founded2014
HeadquartersBedford, Massachusetts, United States
SectorBiotechnology
Websitestoketherapeutics.com
Analyst Ratings
Based on 8 analysts giving stock ratings to STOK in the past 3 months
Strong Buy
Buy
8
Hold
0
Sell
0
12 month forecast
Based on 8 Wall Street analysts offering 12 month price targets for STOK in the last 3 months.
Highest
Current $31.11
$60.00 (+92.86%)
Average
$47.83 (+53.74%)
Lowest
$38.00 (+22.15%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Marc Goodman
Leerink Partners
Buy
Maintained
-
-
06/02/2026
Thomas Shrader
BTIG
Buy
Maintained
$39.00
+25.4%
05/11/2026
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
$50.00
+60.7%
05/08/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Maintained
$60.00
+92.9%
05/08/2026
Laura Chico
Wedbush
Buy
Maintained
$38.00
+22.1%
05/08/2026
Joseph Stringer
Needham
Buy
Maintained
$40.00
+28.6%
05/08/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$60.00
+92.9%
05/07/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
05/07/2026
Rudy Li
Wolfe Research
Buy
Initiated
$40.00
+28.6%
02/23/2026
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.79 / -$0.80
+1.86%beat
Revenue / Est. (USD)
6.23M / 5.13M
+21.42%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
13.82M
10.63M
1.40M
6.23M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
25.86M
37.70M
41.70M
39.67M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.26M
16.03M
21.15M
19.97M
Operating expense
41.12M
53.72M
62.84M
59.65M
Total operating expenses
41.12M
53.72M
62.84M
59.65M
Operating income
-27.30M
-43.09M
-61.44M
-53.42M
Other non operating income
28.00K
3.00K
-110.00K
18.00K
EBT including unusual items
-23.48M
-39.62M
-57.93M
-50.00M
EBT excluding unusual items
-23.48M
-39.62M
-57.93M
-50.00M
Income tax expense
-
-1.28M
-
-
Effective tax rate
-
3.23%
-
-
Other operating expenses
-
-
-
-
Net income
-23.48M
-38.35M
-57.93M
-50.00M
Net profit margin
-169.96%
-360.68%
-4,132.24%
-802.75%
Earnings per share
-0.40
-0.65
-0.97
-0.79
Interest and investment income
3.79M
3.47M
3.62M
3.42M
Interest expense
-3.00K
-3.00K
-3.00K
-23.00K
Net interest expenses
3.79M
3.46M
3.62M
3.40M
Depreciation and amortization charges
-
-
-
-
EBITDA
-26.85M
-42.65M
-61.03M
-52.98M
Gain or loss from assets sale
-
-8.00K
153.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer